

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2016				
Particulars	3 months ended			Year ended
	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	Unaudited			Audited
1. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	8,523	6,882	6,650	27,454
(b) Other Operating Income	220	148	94	478
Total Income from Operations (Net)	8,743	7,030	6,744	27,932
2. Expenses				
(a) Cost of Materials Consumed	2,034	1,309	1,311	6,025
(b) Purchases of Stock-in-Trade	1,786	960	777	3,360
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(750)	(25)	290	(241)
(d) Employee Benefits Expense	1,819	1,822	1,777	7,413
(e) Depreciation and Amortisation Expense	268	251	255	1,015
(f) Other Expenses	2,577	2,464	2,054	9,027
Total Expenses	7,734	6,781	6,464	26,599
3. Profit from Operations before Other Income and Finance Costs	1,009	249	280	1,333
4. Other Income	18	1	28	78
5. Profit from Ordinary Activities before Finance Costs	1,027	250	308	1,411
6. Finance Costs	40	25	94	249
7. Profit from Ordinary Activities before Tax	987	225	214	1,162
8. Tax Expense (including Deferred Tax)				
a. Current Tax	213	47	36	224
b. MAT Credit Entitlement	(213)	(47)	(36)	(224)
9. Net Profit for the period	987	225	214	1,162
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				12,036
12. Earnings per Share (of Rs. 8 each) (not annualised):				
(a) Basic	5.97	1.36	1.29	7.03
(b) Diluted	5.97	1.36	1.29	7.03

Notes:

- The above results have been reviewed by the Audit Committee at its meeting held on 26th July, 2016 and approved by the Board of Directors at its meeting held on 27th July, 2016.
- The results for the quarter ended 30th June, 2016 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company has entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of Biotech Business Unit, as a going concern on a slump sale basis, at a consideration of Rs. 2,487 lakhs, to be received on the closing date. The Closing date being July 6, 2016, no effect has been given in the financial result for the current quarter in respect of aforesaid sale of Biotech Business Unit. The same has been considered as discontinuing operations in accordance with Accounting Standard - 24 - "Discontinuing Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	3 months ended			Year ended
	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	Unaudited			Audited
a) Net Sales	643	843	419	2,437
b) Direct Expenses	496	562	448	2,114
c) Profit/(Loss) from ordinary activities before tax	147	281	(29)	323
d) Tax Expense (net off MAT Credit Entitlement)	-	-	-	-
e) Net Profit/(Loss)	147	281	(29)	323

- There are no exceptional and extraordinary items.
- Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
Mumbai, 27th July, 2016